Abstract
Abstract Acute myeloid leukemia (AML) is a malignant disease caused by disorder of progenitor cells in myeloid hematopoiesis. The rapid progress and high fatality make it difficult to cure the patients suffering from AML. Choice of treatment is limited, consisting primarily of chemotherapy and hematopoietic stem cell transplantation. Pharmaceutical companies are focused on designing new drugs that may be efficacious in treating the disease and prolong the survival of the patients. However, the lack of AML model and specific biomarkers hinder the progress of research on this cancer type. Here we successfully validated subcutaneous and systemic models derived from a number of AML cell lines, such as MV4-11, HL-60, Molm-16, and ML-2, in NOD/SCID mice to evaluate the antitumor activities of new compounds. Biomarkers, such as CD45, CD38 and CD15 in PBMC, spleen and bone marrow from the systemic models, are used in detecting and monitoring the disease progress. These biomarkers correlated with tumor take rate, disease progression and response to standard of care treatments. In conclusion, AML xenograft models with biomarker strategies provide valuable platforms for the development of new compounds targeting this deadly disease. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 1349. doi:1538-7445.AM2012-1349
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
